Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
Revenue of Strides Pharma Science Limited (STAR.NS)
Revenue in 2023 (TTM): $481.84 M
According to Strides Pharma Science Limited's latest financial reports the company's current revenue (TTM) is $481.84 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Strides Pharma Science Limited
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $481.84 M | $171.13 M | $88.4 M | $6.99 M | $-14,847,780 |
| 2022 | $438.7 M | $245.2 M | $19.45 M | $-34,040,683 | $-27,463,171 |
| 2021 | $359.44 M | $171.13 M | $-5,877,192 | $-77,610,021 | $-56,407,386 |
| 2020 | $386.69 M | $219.13 M | $78.88 M | $32.76 M | $31.93 M |
| 2019 | $315.99 M | $175.17 M | $47.09 M | $6.5 M | $4.33 M |
| 2018 | $350.13 M | $171.25 M | $42.58 M | $8.57 M | $38.61 M |
| 2017 | $332.62 M | $163.19 M | $53.4 M | $9.51 M | $78.56 M |
| 2016 | $399.13 M | $215.62 M | $96.53 M | $35.34 M | $47.55 M |
| 2015 | $360.52 M | $178.45 M | $67.75 M | $30.63 M | $24.85 M |
| 2014 | $134.64 M | $67.98 M | $28.42 M | $17.67 M | $100.5 M |
| 2013 | $127.6 M | $54.43 M | $24.39 M | $8.73 M | $-22,206,800 |
| 2012 | $262.2 M | $143.5 M | $62.86 M | $112.93 M | $100.65 M |
| 2011 | $300.27 M | $124.67 M | $62.95 M | $32.43 M | $26.7 M |
| 2010 | $201.7 M | $97.22 M | $47.07 M | $22.17 M | $14.56 M |
| 2009 | $155.19 M | $65.21 M | $18.21 M | $17 M | $13.05 M |
| 2008 | $121.36 M | $51.57 M | $73.46 M | $13.66 M | $12.84 M |
| 2007 | $86.3 M | $36.62 M | $20.83 M | $-4,111,643 | $-5,961,401 |
| 2006 | $88.37 M | $42.62 M | $16.77 M | $7.91 M | $4.78 M |
| 2005 | $62.29 M | $33.66 M | $14.03 M | $7.04 M | $5.78 M |
| 2004 | $53.35 M | $26.34 M | $12.62 M | $6.43 M | $5.23 M |